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Abstract
Background: Accurate whole-body staging following biochemical relapse in prostate cancer is vital in determining
the optimum disease management. Current imaging guidelines recommend various imaging platforms such as
computed tomography (CT), Technetium 99m (99mTc) bone scan and 18F-choline and recently 68Ga-PSMA positron
emission tomography (PET) for the evaluation of the extent of disease. Such approach requires multiple hospital
attendances and can be time and resource intensive. Recently, whole-body magnetic resonance imaging (WB-MRI)
has been used in a single visit scanning session for several malignancies, including prostate cancer, with promising
results, providing similar accuracy compared to the combined conventional imaging techniques. The LOCATE trial
aims to investigate the application of WB-MRI for re-staging of patients with biochemical relapse (BCR) following
external beam radiotherapy and brachytherapy in patients with prostate cancer.
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Methods/design: The LOCATE trial is a prospective cohort, multi-centre, non-randomised, diagnostic accuracy
study comparing WB-MRI and conventional imaging. Eligible patients will undergo WB-MRI in addition to
conventional imaging investigations at the time of BCR and will be asked to attend a second WB-MRI exam, 12-
months following the initial scan. WB-MRI results will be compared to an enhanced reference standard comprising
all the initial, follow-up imaging and non-imaging investigations. The diagnostic performance (sensitivity and
specificity analysis) of WB-MRI for re-staging of BCR will be investigated against the enhanced reference standard
on a per-patient basis. An economic analysis of WB-MRI compared to conventional imaging pathways will be
performed to inform the cost-effectiveness of the WB-MRI imaging pathway. Additionally, an exploratory sub-study
will be performed on blood samples and exosome-derived human epidermal growth factor receptor (HER) dimer
measurements will be taken to investigate its significance in this cohort.
Discussion: The LOCATE trial will compare WB-MRI versus the conventional imaging pathway including its cost-
effectiveness, therefore informing the most accurate and efficient imaging pathway.
Trial registration: LOCATE trial was registered on ClinicalTrial.gov on 18th of October 2016 with registration
reference number NCT02935816.
Keywords: Magnetic resonance imaging, Prostate cancer, Radiotherapy, Brachytherapy, Recurrence, Positron
emission tomography, Cost comparison, Cost-effectiveness, Economic evaluation
Background
Prostate cancer (PCa) is the leading male cancer in the
United Kingdom and a principal cause of cancer-related
mortality with around 46,700 cases diagnosed in 2014
[1]. The incidence of PCa has increased markedly over
the past 20 years and it is projected to rise by 12%
between 2014 and 2035 to 233 per 100,000 males [1].
Common treatments options for localised prostate can-
cer are external beam radiation therapy (EBRT), brachy-
therapy (BRT) or radical prostatectomy [2].
However, biochemical recurrence (BCR) following
radiotherapy occurs in 25% of treated men within 5
years, manifesting as a rising prostate-specific-antigen
(PSA) [3]. This is strictly a biochemical diagnosis, most
commonly defined as an increase in serum PSA of 2.0
ng/ mL above the nadir [4]. Once a PSA relapse has
been diagnosed, it is important to determine whether
the recurrence has developed at local or distant sites and
hence BCR following therapy often initiates an imaging-
based assessment of local and metastatic disease in
patients.
Local recurrence of PCa is investigated by prostate
multi-parametric magnetic resonance imaging (mp-MRI)
[5] whilst metastatic disease is assessed by multi-
modality imaging. The standard workup to detect PCa
metastases usually includes 99mTc bone scan and chest/
abdomen/pelvis (CT-CAP) scan (or where available
18F-choline or 68Ga-PSMA PET-CT) [6].
The workup to exclude distant metastasis is of greatest
significance as it is estimated that about half of those
who develop radio-recurrent disease have distant metas-
tases (either overt on imaging or micro-metastases) [7].
It is also believed that up to 50% of men who are
considered to be free of metastases by conventional sta-
ging methods have micro-metastatic disease [8]. This is
reflected in prostate cancer recurrence following EBRT
or BRT, where biochemical relapse commonly precedes
clinical detection of metastases by an average of
7–8 years [9].
Earlier detection of metastatic disease could be the
key to better patient stratification and well-informed
patient management either by opting for active sur-
veillance or local salvage for low risk individuals or
offering systemic therapy at an earlier time point to a
high-risk population [10].
Recent technological advances have enabled the re-
liable whole-body MRI (WB-MRI) staging of cancers
within a reasonable scanning time (less than 1 h)
[11–14]. There is a clear need for an imaging modal-
ity that is capable of improved sensitivity for meta-
static disease detection than current conventional
imaging [15–17]. Previous meta-analysis has reported
the sensitivity of 99mTc bone scan to be less than
50% [18]. Similarly, studies have shown the sensitiv-
ity of 18F-choline PET to be as low as 50% for the
detection of nodal disease when PSA is < 5 ng/ml
[19]. Furthermore, CT Scan sensitivity for nodal
disease detection in prostate cancer is reported to be
much lower with a meta-analysis reporting a sensi-
tivity of 30% [20].
The LOCATE study investigates the diagnostic per-
formance of WB-MRI for detection of nodal and meta-
static disease compared to current standard multi-
modality imaging comprising 18F-choline PET-CT and
99mTc bone scan (+/− CT-CAP) in patients with the
radio-recurrent PCa.
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Study objectives
Primary objective
To compare the diagnostic accuracy of WB-MRI for
regional lymph node and distant metastatic disease
detection against an enhanced reference standard of 18F-
choline PET-CT (or CT CAP) and 99mTc bone-scan for
men presenting with BCR following EBRT or BRT.
Secondary objectives
1. Inter-observer agreement of WB-MRI for regional
lymph node and distant metastatic disease detection
2. Derivation and evaluation of apparent diffusion
coefficient (ADC) and fat fraction (FF) signal
heterogeneity indices of metastatic disease as
predictors of treatment response to ADT
3. Exploration of the significance of the Human
Epidermal growth factor Receptor (HER) activated
dimer in metastatic castration-resistant prostate
cancer
4. Cost-effectiveness of WB-MRI for radio-recurrent
prostate cancer staging compared with conventional
imaging modalities
Methods/design
Study design
The comparative diagnostic accuracy study will conform
to the Standards for Reporting of Diagnostic Accuracy
(STARD) statement [21]. The study is a prospective co-
hort multi-centre diagnostic study where all participants
will have WB-MRI and conventional imaging tests (18F-
choline PET or CT-CAP and 99mTc bone scan) with
findings of both validated against an enhanced outcome-
based reference standard. The patient recruitment flow-
chart is illustrated in Fig. 1.
Sample size
Based on 50% prevalence of metastases, 130 patients will
be required to demonstrate a minimum of a 20% differ-
ence in sensitivity for detection of metastases on a per-
patient level between WB-MRI and combination of 18F-
choline PET-CT and 99mTc bone scan (power of 90%
and statistical significance cut-off of 0.05).
Ethical approval
The LOCATE trial received UK Research Ethic Commit-
tee (REC) approval from the National research ethics
service (NRES) Committee London-Chelsea with REC
reference 15/LO/0776 and will be conducted in accord-
ance with the principles of ICH guidelines on good
clinical practice in clinical trials and the Research
Governance Framework for Health and Social Care
(England).
Recruitment
Inclusion criteria
Men who have undergone previous EBRT or BRT with
or without neo-adjuvant/adjuvant hormone therapy.
Biochemical relapse as determined by increase in PSA.
Exclusion criteria
Men unable to have MRI scan, or in whom artefact
would significantly reduce quality of MRI.
Men unable to give informed consent.
Informed consent
In all cases, patient information sheets and sample con-
sent forms will be made available to patients a minimum
of 24 h prior to the consent procedure. Consent will be
obtained at the time of the appointment and prior to
commencement of any trial intervention.
Trial interventions
Whole body MRI
Recruited patients will have WB-MRI scan on presenta-
tion with BCR and then at 12 months (follow-up). All
WB-MRI scans will be performed at University College
London Hospital NHS foundation trust (UCLH) imaging
department on a 3.0 T scanner (Ingenia; Phillips Health-
care, Best, Netherlands), using a fixed protocol (Table 1).
For participants’ comfort, the WB-MRI protocol will be
limited to a maximum of 1-h scan time.
Conventional imaging
Recruited patients will have the standard imaging investiga-
tions according to local and national guidelines as below:
Multi-parametric prostate MRI
A standard prostate mp-MRI protocol as defined by the
UK consensus guidelines on prostate MRI [22] will be
used to locally stage prostate cancer. Conventional T1
and T2-weighted images of the prostate will be supple-
mented with diffusion weighted imaging (DWI) MRI (as
per hospital site protocol); and +/− dynamic contrast
enhanced (DCE) T1-weighted images.
Computed tomography
CT scans of the chest/abdomen/pelvis will be performed
with intravenous contrast agent using the local standard
protocols.
99mTechnetium bone scan
Bone scans will be performed using 99mTc labelled dipho-
sphonates administered through intravenous injection.
For prostate cancer patients with suspected bone metasta-
ses, the standard protocol employed at the hospital site
will be used. As a guide, whole body imaging will be
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conventionally performed with anterior and posterior
views, 256 × 1024 matrix and energy window(s) of 140
KeV.
Positron emission tomography-computed tomography (PET-CT)
18F-choline PET-CT will be acquired using a dedicated
combined PET/64-detector-CT (VCT-XT Discovery, GE-
Healthcare Technology, Chicago, Illinois), CT will be per-
formed (for attenuation correction) using 64 × 3.75mm
detectors, a pitch of 1.5 and a 5mm collimation (120 kVp
and 10mA in 0.8 s). Maintaining the patient position, a
whole-body choline PET emission scan will be performed
and cover an area identical to that covered by CT [23].
Non-imaging trial interventions
Blood samples
Blood samples will be taken from recruited patients, by
an appropriately trained member of the trial team, at the
time of each WB-MRI (staging and then at 12-month
follow-up). Blood samples will be used for exosome and
phenotypic [Fluorescence-activated cell sorting (FACS)
analysis] / DNA-RNA analysis. In total a maximum of
30ml of blood will be taken:
Up to 3 acid citrate dextrose solution (ACD) tubes: to collect
~ 15 ml blood for serum separation
Up to 3 ethylenediaminetetraacetic acid (EDTA) con-
taining tubes for peripheral blood mononuclear cells
Fig. 1 Trial flowchart. The trial flowchart describing the standard of care pathway through which patients were reviewed and clinical decisions
made. A parallel research pathway was designed to mimic the standard pathway without interfering in patient care except when clinically
significant incidental findings are identified
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(PBMC) isolation and further FACS analysis, functional
assays, and DNA/RNA isolation.
Frozen aliquots-samples will be transported by courier
service in dry ice-containing carrier boxes within 24 h
after obtaining the blood sample. Samples will be proc-
essed at University College London (UCL) and King’s
College London (KCL) laboratories:
UCL: Exosome purification and analysis. Protein-
DNA-RNA isolation and analysis.
KCL: PBMC’s isolation, FACS analysis and functional
assays.
Health economic data collection
Data collection for the health economic analysis will be
primarily concerned with cost data associated with the
diagnosis and treatment of metastatic prostate cancer.
Routinely collected administrative data from UCLH will
be used to determine the relevant costs associated with
the diagnostics test. To determine the consequence of de-
tected metastatic disease on the treatment pathway, clin-
ical experts will be interviewed, and patient notes will be
reviewed noting changes to medication, radiotherapy, sur-
gery, outpatient visits, inpatient visits and day cases, where
possible. Data from existing trials such as STAMPEDE
[24] and FORECAST [7] will be used to inform other eco-
nomic parameters such as the health-related quality of life
as these are not being collected in LOCATE.
Reporting of trial imaging
Initial WB-MRI scan
The study will be reported by two experienced radiolo-
gists, blinded to all other imaging investigations, initially
independently and then in consensus using a locked
sequential read paradigm (LSR). The images will be
reviewed for the presence of nodal (N) and metastatic (M)
disease and each radiologist will record the presence/ab-
sence of disease on the study-specific proforma.
The initial WB-MRI read results will not be revealed
to the clinical team. Where a significant additional/inci-
dental finding is demonstrated this will be reported as
per standard clinical practice and relayed to the clinical
team.
A 1–6 Likert scale [23, 25] will be used for scoring as
has been previously described for WB-MRI studies. 1 –
disease definitely not present, 2 – probably not present,
3 – possibly not present, 4 – disease possibly present,
5 – probably present and 6 – definitely present.
Scoring will be conducted based on evaluation of im-
aging features of lymph nodes and bone metastases as
indicated below in Table 2 .
12-month follow-up WB-MRI
The study will be reported by the same pair of radiolo-
gists who reported the baseline scans. The findings on
the follow-up study will be compared with the baseline
WB-MRI with access to all conventional imaging. The
presence of changes in size of lesions evident on the
baseline WB-MRI and/or resolution of lesions evident
on baseline WB-MRI will be recorded. Any discrepant
findings will be reviewed, and the status of these lesions
will be determined in a consensus panel review.
Derivation of enhanced reference standard
Figure 2 illustrates the derivation of a per-patient level
enhanced reference standard (ERS).
Patients will be divided into those with and without
metastases evident on conventional imaging. For those
with metastases (left arm of Fig. 2), concordant positive
WB-MRI findings will be deemed to be true positive and
discordant WB-MRI findings will be considered to be
false negative.
Table 1 Whole Body MRI sequence parameters
T2-TSE mDixon (pre- and post-contrast) DWI (b0, 1000)
Slice orientation Transverse Coronal Transverse
Echo time (ms) 80 2.303 17
Repetition time (ms) 1214.69 3.5 6304.5
Space between slices 5.5 2.5 5.5
Number of slices 40 120 40
Slice thickness (mm) 5 5 5
Acquisition matrix 500*497 240*238 124*118
Echo train length 89 2 39
Number of averages 1 1 2
Pixel bandwidth (Hz) 538 1847 3354
Pixel spacing 0.78/0.78 1.04/1.04 2.08
Flip angle 90 15 90
TSE Turbo spin echo, DWI Diffusion weighted imaging
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For patients without metastases on conventional im-
aging (right arm of Fig. 2), clinical and biochemical
follow-up together with changes between baseline and
follow-up WB-MRI will be used to enhance the
reference standard.
Where baseline WB-MRI was negative and concordant
with conventional imaging, the presence of new lesions (at
follow-up WB-MRI ± repeat routine imaging) coupled
with a PSA rise over the 12-month will classify the base-
line WB-MRI as false negative, i.e. disease was present but
not visualised. Whereas the absence of new lesions regard-
less of PSA status over the 12-month follow-up period will
confer baseline WB-MRI true negative status.
For positive findings on baseline WB-MRI discordant
with conventional imaging, the baseline WB-MRI will be
deemed true positive when a new lesion declared itself
(on follow-up WB-MRI ± routine imaging) or the visua-
lised lesion on baseline WB-MRI enlarged (on follow-up
WB-MRI); and this was accompanied with a PSA rise
within the 12-month follow-up period. Whereas, the
Table 2 Features suggestive of adverse and benign changes in both nodes and bones
Benign features Adverse features
Node Lymph node <5mm in short axis diameter (SAD) with no concerning
features on DWI, T2 weighted or contrast enhanced imaging and definite
benign features e.g.
(i) Fatty hilum,
(ii) Oval nodal morphology with clearly defined and
(iii) Regular nodal border and contours.
Concerning features could be described as
(i) Size above normal limit e.g. > 10 mm for most,
(ii) Loss of fatty hilum,
(iii) Irregular border,
(iv) Asymmetric high DWI signal intensity,
(v) Low T2 signal
Bone Normal appearing bone with uniform moderate-high signal on T1
weighted imaging and low-moderate signal on T2 weighted imaging.
Focal lesions demonstrating clearly incidental/benign multiparametric
signal characteristics and/or location
(i) Increase in DWI high b-value signal vs. background noise.
(ii) Low signal intensity on T1 and (iii) Intermediate to high signal
intensity on T2
(iv) Lesional contrast enhancement
DWI Diffusion weighted imaging
Fig. 2 Enhanced reference standard derivation flowchart. FN: False Negative, TP: True Positive, FP: False Positive, TN: True Negative, UK: Unknown,
ADT: Androgen Deprivation Therapy
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baseline WB-MRI will be deemed false positive when
the lesion evident at WB-MRI resolved or reduced in
size at follow-up (in the absence of systemic therapy) re-
gardless of PSA change. Lesions that resolved following
systemic therapy (which is initiated in the 1-year follow-
up period irrespective of negative conventional baseline
imaging) with corresponding decrease in PSA will be
classified as true positive.
Finally, patients with negative baseline conventional
imaging with discordant lesion and PSA changes over
the 12-month follow-up (i.e. lesion size/number increase
without corresponding PSA increase) will be classified as
unknown.
The section below describes the thresholds for PSA
and lesion size changes, and they will be interpreted in
the context of treatment intervention and subsequent
treatment response or progression.
PSA progression defined as ≥25% and ≥ 2 ng/mL in-
crease in PSA recorded at least 12 weeks from baseline
or start of treatment and confirmed on a 2nd reading
3–4 weeks later as previously defined [26, 27].
PSA response defined as ≥50% decline from baseline
or start of treatment and confirmed on a 2nd reading
3–4 weeks later [28, 29].
Nodal size change Increase of ≥2mm and decrease of
≥3mm in short axis diameter on contrast enhanced
mDixon sequence will be considered true change
(progression and response respectively) rather than a
measurement variation, with a 95% confidence interval.
(Based on unpublished data from repeatability studies
carried out as part of the LOCATE trial).
Bone lesion (disease progression) ≥ 25% increase in
size (sum of short and long axes diameters) of lesions on
CT, or MRI [30, 31].
Bone lesion (treatment response) ≥ 50% decrease in
size (sum of short and long axes diameters) of lesions on
CT/ MRI or normalisation of signal intensity on MRI
[30, 31].
Soft tissue lesion size change (disease progression) At
least a 20% increase in size of lesion taking as reference
the baseline diameter of the lesion [32].
Soft tissue lesion size change (treatment response)
at least a 30% decrease in the size of lesion, taking as
reference the baseline diameter or disappearance of
the lesion [32].
Image analysis
Reporting of conventional imaging
The conventional imaging (18F-choline PET-CT, CT-
CAP and 99mTc Bone Scan) will be independently re-
ported by two radiologists and nuclear medicine physi-
cians, later reviewed in consensus to clarify any
discrepant findings. The report will be transferred to a
proforma and final nodal (N) and metastatic (M) stages
will be derived base on the reported proforma.
Comparison of conventional imaging with WB-MRI
The research team will correlate the conventional im-
aging proforma with the baseline WB-MRI proforma
and follow-up WB-MRI findings. The radiologists and
nuclear medicine physicians in consensus will review all
discrepancies, between conventional and WB-MRI scans.
Anatomical matching errors resulting from discrepancies
in ascribing disease location will be recorded and cor-
rected [33]. Residual discrepancies will be highlighted,
categorised as perceptual and technical and statistically
assessed [33]. The per-patient sensitivity and specificity of
WB-MRI will be determined against the enhanced refer-
ence standard before and after correction for any anato-
mical matching discrepancies and perceptual errors.
Patients who are unable to attend the 1 year follow up
WB-MRI may not be included in the diagnostic accuracy
analysis. Efforts will be made to minimise amount of miss-
ing data. A statistician’s advice will be sought especially on
how to manage ‘missing not at random’ data (if any).
Sub-study analysis
The significance of the human epidermal growth factor
receptor (HER) activated dimer
The blood sample will be used to investigate the signifi-
cance of the Human Epidermal growth factor Receptor
(HER) activated dimer in recurrent prostate cancer. Up-
regulation of the HER1 (EGFR)/HER3 dimer was
recently found, for the first time, to limit the efficacy of
anti- epidermal growth factor receptor (EGFR) treatment
in human breast cancer, as directly shown by imaging of
residual disease; suggesting the potential of combined
EGFR/HER3-targeted treatment [34]. This molecular
signalling rewiring is hypothesised to constitute a path-
way of resistance to hormonal treatment in prostate can-
cer as well. We intend to quantify the EGFR/HER3
heterodimer using fluorescence lifetime imaging micros-
copy (FLIM) in formalin-fixed prostate cancer tissues as
well as in matched circulating exosomes from patient-
derived plasma. We will then correlate the heterodimer
quantification with tumour genomic changes such as
phosphatase and tensin homolog (PTEN) mutation/dele-
tion. The patient-derived correlative experiments will be
complemented by mechanistic in vitro experiments that
investigate the effect of EGFR and phosphatidylinositol
3-kinase (PI3K)/AKT inhibitors on HER dimer forma-
tion in castration-resistant and sensitive prostate cancer
cells, and their exosomes released into the culture super-
natants. In the clinical setting, the tissue and exosome-
derived HER dimer measurements will be combined
with WB-MRI findings to assess their value and
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translation as predictive biomarkers of clinical outcome
and response to treatment.
Heterogeneity (across metastatic sites) of WB-MRI signals
for prediction of ADT response
For patients undergoing ADT treatment, retrospective
quantitative analysis of WB-MRI’s ADC and FF signal
intensities will be performed to derive heterogeneity in-
dices across confirmed true positive metastatic sites. The
heterogeneity indices will inform Bayesian models to
predict high-risk patients with aggressive disease that
progress on ADT within 12-months of treatment.
Health economic analysis
The health economic analysis will compare the incre-
mental costs and effects of WB-MRI for metastatic dis-
ease detection compared with conventional imaging
from a national health service (NHS) perspective and
thus determine whether it is an efficient use of NHS re-
sources. From an economic viewpoint, the cost-
effectiveness of WB-MRI versus conventional imaging is
determined by two main stages of the pathway: the treat-
ment decision pathway and the treatment pathway (and
its associated disease pathway). The former includes the
time from presentation to treatment decision by the
clinician and includes the imaging tests received; the lat-
ter includes the time period following the treatment de-
cision and subsequent disease progression. In patients
for whom the treatment decision with WB-MRI is the
same as that with conventional staging, the subsequent
disease pathways will be the same. Where the treatment
decision with WB-MRI is different, the disease pathway
will be different, yielding potentially different costs and
health outcomes (and hence the patient’s quality of life).
The precise nature of the economic analysis will there-
fore depend on the degree of concordance between
treatment decisions provoked by WB-MRI versus con-
ventional imaging.
Scenario 1
There is concordance between the treatment decisions
associated with WB-MRI and conventional imaging. In
this case, the cost components included in the analysis
will be conventional metastases imaging tests (as de-
scribed above) and the costs of treating adverse events
associated with conventional staging. The volume of re-
source use and unit costs will be taken from standard
published sources, hospital administrative datasets and
from trial data. Since the two algorithms yield the
same treatment decisions, cost-effectiveness depends
on the incremental cost only of WB-MRI versus
conventional imaging.
Scenario 2
There is discordance between the treatment decisions
associated with WB-MRI and standard imaging. In this
case, cost-effectiveness depends on the incremental cost
and effects of the treatment decision pathway and the
subsequent disease pathway associated with WB-MRI
versus conventional staging.
The economic evaluation will also take into consider-
ation the accuracy of WB-MRI versus conventional
standard imaging techniques. Specifically, we will model
the consequences, in both costs and effects, of true posi-
tives, false positives, true negatives and false negative
outcomes. Thus, the economic study will evaluate both
clinical and economic consequences of the novel im-
aging technique.
Cost-effectiveness will be calculated as the mean cost
difference between WB-MRI versus conventional im-
aging divided by the mean difference in outcomes (as
measured quality-adjusted life years; QALYs) to give the
incremental cost-effectiveness ratio (ICER). Also, a cost-
consequence analysis will be performed by calculating
the mean incremental costs per incremental gain (or
loss) in clinical natural units, for example cost per me-
tastases identified.
Finally, to address uncertainty in our clinical and eco-
nomic parameters, we will perform a comprehensive set
of sensitivity analyses on our model estimates. Probabil-
istic sensitivity analysis using non-parametric bootstrap-
ping methods will be performed. Outputs from this will
inform a cost-effectiveness acceptability curve, which
shows the probability that WB-MRI is cost-effective at
different values of the NHS’ willingness to pay for an
additional QALY. We will also subject the economic
model to extensive one-way sensitivity analysis to
identify key parameters that drive cost-effectiveness.
Discussion
At the time of writing, the LOCATE trial is the largest
prospective multi-centre trial to compare WB-MRI with
conventional imaging pathway specifically in patients
with radio-recurrent prostate cancer.
The LOCATE trial will be informative because it com-
pares comprehensive imaging pathways and takes into
consideration the cost-effectiveness of each pathway.
This trial will therefore provide valuable information to
guide potential implementation of new imaging plat-
forms for prostate cancer management pathways.
The results from the LOCATE trial would be relevant
to the current clinical management pathway, specifically,
should WB-MRI be advocated in the NHS in the setting
of BCR.
The LOCATE trial design includes important features:
unlike most other trials, the initial finding on WB-MRI
will be validated using 1 year follow up WB-MRI scans,
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corroborating the findings on initial scan in the context
of patient management. In this way, we minimise the po-
tential overcalling of disease positivity by WB-MRI that
could lead to an overestimated sensitivity of WB-MRI
compared to conventional imaging techniques.
Additionally, and in order to define the most cost-
effective imaging pathway for the health care system, we
will perform an economic evaluation which includes a
comprehensive set of sensitivity analyses to identify un-
certainty in both clinical and economic estimates. Whilst
recent trial designs incorporating WB-MRI are including
health economic analysis [35–38], such information is
still unavailable for prostate cancer imaging pathways.
The LOCATE study has some potential limitations.
Firstly, we are using a combined biochemical/imaging
follow-up to derive an enhanced reference standard
against which the results of WB-MRI will be analysed.
Although histopathological confirmation would have
been preferable in cases where a discrepancy exists be-
tween WB-MRI and conventional imaging tests, such
approach is technically challenging and ethically not
feasible [39].
Secondly, whilst the qualitative and metastatic staging
findings can be generalised to other imaging platforms,
such generalisability would be limited in quantitative
biomarker imaging analyses (heterogeneity index). How-
ever, ongoing work is being carried out to improve
standardisation of quantitative MRI imaging across dif-
ferent platforms that could ultimately aid in generalisa-
tion of such technique [39, 40].
Finally, it is important to note that 68Ga-PSMA
PET-CT within a short time has led to significant ad-
vances in prostate cancer imaging both in primary
and recurrent settings [41, 42]. However, there is yet
to be large prospective multi-centre studies to assess
its diagnostic accuracy in comparison to WB-MRI,
and the start of the LOCATE trial predated availabi-
lity of 68Ga PSMA PET-CT at our institution and
therefore a head to head comparison was not pos-
sible. More importantly, there is significant cost
difference between the two modalities and PSMA is
routinely not available in many centres in the UK.
Study status
At the time of submission, the study is currently at the
data collection stage and full trial data analysis is ex-
pected to begin shortly.
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